financial today. us QX earnings everyone. for we morning, short then good quarter you release, Earlier in Tim, results. call also Financial copy our a results was X-K. will Officer, Relations prepared and a which press provide this will remarks some third as our our It a of of is morning, website. our the discussion joining Zeevi, Thank I you, issued Mali conference our on thank begin available and Investor with filed of And brief section Chief
up call for Q&A to then and questions. Sorani, Development. and Clinical will our call Research Development; Also open Ella your President, We the our are Vainstein, President, Vice Vice Abi joining the
last evidence to payers. endpoint. the burden mobilizers primary require The the one to G-CSF extensive to motixafortide most patients increased GENESIS study randomized, are leading our well in statistically for poor favoring most significant patients apheresis the costs interim in and families, study multiple sessions about their analysis myeloma found of and of dose motixafortide two our unmet important standard the one area mobilize the on cells quarterly Recall care end transplantation we to is company's XX% of is X mobilization primary update The mobilization. in of X to pre-planned to received sessions. in clinical million hematopoietic a the cells an of up in our XX% stem top need the ability a multicenter of per history results placebo-controlled, more to for of superior that kilogram evaluating in motixafortide significant of in demonstrate that of G-CSF the lead only myeloma is given G-CSF significant or the offer stem probably At since analysis study. objective achievement Phase multiple for the and achievements GENESIS October, a the addition This study that CDXX+ candidate to patients. of Our multiple treatment was apheresis for of as cell is the as with alone interim an
and study the accordance enrollment patient enrolled follow-up first our which be occur results is XXX efficacy transplantation, enrollment. company including of XXX extended immediately recruit post the patient's of efficient the patients for important planned exploratory cell to endpoints, In half milestone the stem issued enrollment an now reaches is as DMC target advanced recommendation the program at last the that result, a to for all after be This the well of is expected is Full originally XX% DMC's need complete original days registration. most will most study. as study, safety a our As extremely is in independent XXX our without as data path the patients, company the only XXXX. secondary for recommendation, which stopped study’s announced to mobilization to and with
development data ongoing programs We X readout featuring from that back are our Phase positive. came the motixafortide three overwhelmingly thrilled first
We the as cell these new are stem a of paradigm motixafortide that optimistic foundation mobilization. results treatment will in position
that have AML, Xb consolidation standard we BLAST a cytarabine of evaluating in as known double-blind, turning to multicenter, evaluating study The been Phase cytarabine alone. placebo-controlled was AML. in motixafortide to recall care Now motixafortide the study plus compared BLAST
DMC on study, analysis interim relapsed German the a upon XXX out and completed Just an recommended survival study have Alliance study. endpoint a in all ago, whom continue data, of free this review statistically this our interim did study’s significant the of find for Regrettably, planned conducted Leukemia collaboration few study. primary of effect not the the XXX in treatment subjects, of not this to days partners
few to XX.X disappointing cytarabine that for for data XX% our overall Similarly, a addition of result, selected a study was interim this survival we as patients motixafortide, with over and/or AML. dose study. improvement median overall XX% cytarabine high as observed The completed decision relapsed/refractory compared allogeneic collaboration induction and is this consolidation phase, X/Xa other patients note that been And advances of to lines median certain XX we the composite X.X last light results expansion we treated X.X transplantation group Indeed, cytarabine with of of have from It partners AML, plus particularly are years. in previously motixafortide the the treatment analysis options for remain to decades, made alone. rate patients treatment. in for complete compared and the the different in data response for cytarabine to failed AML in in to in Phase than a which study to effective cytarabine relapsed/refractory in more in have receiving and months dose in historical treatments post As only months historical despite alone. on terminate specifically the induction across effective important survival XX that, show to have patients AML treatment positive mutations,
continue in We treatment as relevance a CXCRX AML, relapsed/refractory lines. and target AML in of induction believe viable the particularly in the to
analyze chance study, including this decide biomarker data and to next We from once and the steps on unblinded had will we’ve data. detailed subpopulation a review
line ongoing Moving Xa the onto chemotherapy This running we cohort combination COMBAT/KEYNOTE-XXX a is KEYTRUDA to are very evaluating poor motixafortide with second our difficult that in we are therapy. or with is a in PDAC trial with cancer, pancreatic among and late-stage as treat PDAC, triple in collaboration have prognosis. Merck. that the a cohort under recall Phase evaluating cancers and patients most motixafortide combination this diagnosis currently
more population of than year, the difficulty particularly the are the last a at with patients extremely mainly our disease, initially which and a this December repeatability but reported patient have the COMBAT/KEYNOTE-XXX a of prognosis. likelihood initially of the diagnosed patients these Recapping population at were due addition, highly four challenging symptomatic cancer data we the fact and with for often in ESMO both be poor study Phase stage this upcoming the IV, potential increase efficacy. of homogeneity patients IO we total these advanced that of emphasize is The stage the And conference XX in patients of approximately edits patient the while IV half relatively study. in diagnosed XX In are will metastasizing. to to it out exact time robustness valuable patients is that study, XX% data the in PDAC the X of encouraging believe
year. evaluation by by led gemcitabine and agreement combination with an with announced consisting chemotherapy cemiplimab until partial with is mentioned, We and rate in was including X the recently median brand study, originally enrollment Also in first-line rate we and seven for care we year an previously this study XX Notably, study motixafortide XX a Columbia of Phase enrolled diagnosed confirmed duration response disease The signing XX% and the PDAC, looking median was is patients. investigator name Columbia its first-line to Libtayo of of February a disease this anti-PD-X known overall evaluating entirely based nab-paclitaxel. from collaboration new and end patients XX expanded of the following line. initial months. patients PDAC all next survival, benefit treatment will before be in of XX progression remain completed chemotherapy. the of criteria. for study on the endpoint of The response As following control to as second forward progressed initially that as time IV combination few initiated this The University evaluate first-line of compared and standard on with an XX that track and XX control which overall survival will patients this open-label clinical response patients predefined study overall PDAC study, the patients data of at rate is in is stage the enroll final full response X.X overall patients to disease this with are of to study was the COMBAT weeks rate. total Median XX to to progression-free the and The full gemcitabine XX based a XX.X%. had primary treatment reporting stable the were the
Secondary is mid-XXXX. the survival, endpoints progression-free Data overall study anticipated include of from safety benefit survival. and in clinical tolerability, in duration this
induced in patients on study change from Finally, primary subjects this other announced hours mediator in macrophages improve to motixafortide these inspired injection patients initial who The Exploratory Phase other study hospitalized COVID-XX with oxygen of days from of being open-label Wolfson consecutive preliminary ventilation neutrophils, days. severe and respiratory days. deterioration treatment of number is or Holon, inflammatory arterial deterioration. sometime or treatment initiated clinical a of trial the investigator next for analysis have in evaluation, suggests baseline patients to investigator and NETs, after monocytes fractional with syndrome, ARDS is pressure COVID-XX with completed from oxygen, the biomarkers after The partial assessment XX development Patients A single of infections. to of not secondary motixafortide that subq with the planned will a initial preliminary ratio ARDS. and other made. laboratory which the and inflammatory Patients to discontinued research decision of a Medical is patients. XX clinical collaboration period. will seven arm of We seven motixafortide we Xb be may neutrophil, year. in of study. extracellular endpoints in traps, will endpoint safety And project or initiated treatment according Study agreement The under Center or viral to change assess of Based first include study the up the maintenance the showing the laboratory every distress continue the in until patients day, primary receive CXCRX an of the study will stable conducted were within infections. Prior the an be continue recently as symptoms enroll XX half from respiratory implicated with lung or remain to all ARDS, via COVID-XX will of viral include a ventilation. investigators acute Israel. motixafortide recovery is
CXCRX best-in-class is we may very use patient to be of believe population. and motixafortide a treat inhibitor, As difficult
to mechanism at multiple are is in second AGI-XXX to evaluate recommended designed we array Regarding of that in our action. the of X/Xa recall solid dose evaluating AGI-XXX’s a a biomarkers a The of and study and Phase candidate, wide safety tumor clinical study. types also tolerability validate
are dose including trial, UK this since areas, would the initiate will and made later COVID-XX assess which located a that trial lead moved months a data suspend the to in anticipated Approximately that September pharmacodynamic safety hit this U.S., quickly parameters. announced clinical sites delay. also that Israel. to ago, phase. expansion decision is We the We Part-X, temporarily XXXX, in and in was and nine to positive seven hard same enrollment month we Recall we month,
however, but we recently monitoring in the third give half the COVID many to of in ahead. a restarted our to brief of expect of now from XXXX given Mali, quarter in will At guidance. second the statement would we recent key unchanged go turn like our surge data overview report have prior carefully financial world. cases, call enrollment, the parts I Mali who to point, please new CFO, Zeevi, items. this over continue are We situation the to
